Literature DB >> 22019901

Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults.

André M Faria1, Madson Q Almeida.   

Abstract

Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. The incidence of pediatric adrenocortical tumors (ACT) is remarkably high in Southern Brazil, where it is estimated to be 15 times greater than the world occurrence, due to a high frequency of a germline mutation (p.R337H) of the TP53 gene. Differently from adults, pediatric adrenocortical neoplasms with apparently poor prognosis based on histopathological features have often a good clinical outcome. A high Weiss score is definitely not a good predictor of survival in children, but it is much more discriminative of a poor outcome in adult tumors. Besides important differences in prognosis, adrenocortical tumorigenesis has distinct patterns between children and adults. In this review, we summarize recent data from ours and other Institutions, showing that the prognostic importance of molecular markers is striking different between pediatric and adult ACT. Although the majority of pediatric ACT are associated with p.R337H germline mutation, it is not a predictor of poor outcome in children and adolescents with ACT. On the other side, TP53 somatic mutations define a subgroup of adult ACC with different tumorigenesis and unfavorable prognosis. IGF system has a central role in the malignant phenotype of ACT, but in adult tumors it is mediated by IGF2 over-expression and in pediatric tumors by IGF1R over-expression. Finally, SF1 over-expression is associated with decreased overall survival and recurrence-free survival in adult ACC, but not in the pediatric group. In conclusion, discriminating benign and malignant behavior is more challenging in pediatric ACT than in adult tumors. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22019901     DOI: 10.1016/j.mce.2011.09.040

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  14 in total

1.  Management and prognosis of adrenocortical tumors in children: can we find out an appropriate points-scoring system to predict prognosis?

Authors:  Wei Ru; Min Yang; Shan Xu; Minju Li; Daxing Tang
Journal:  Pediatr Surg Int       Date:  2017-03-04       Impact factor: 1.827

2.  Pediatric adrenocortical neoplasms: immunohistochemical expression of p57 identifies loss of heterozygosity and abnormal imprinting of the 11p15.5.

Authors:  Isabella Giovannoni; Renata Boldrini; Maria Chiara Benedetti; Alessandro Inserra; Maria Debora De Pasquale; Paola Francalanci
Journal:  Pediatr Res       Date:  2016-11-14       Impact factor: 3.756

Review 3.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 4.  The role of epithelial growth factors and insulin growth factors in the adrenal neoplasms.

Authors:  Anna Angelousi; Georgios Kyriakopoulos; Narjes Nasiri-Ansari; Margarita Karageorgou; Eva Kassi
Journal:  Ann Transl Med       Date:  2018-06

5.  Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.

Authors:  Jonathan D Wasserman; Ana Novokmet; Claudia Eichler-Jonsson; Raul C Ribeiro; Carlos Rodriguez-Galindo; Gerard P Zambetti; David Malkin
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

6.  Clinical Impact of Pathological Features Including the Ki-67 Labeling Index on Diagnosis and Prognosis of Adult and Pediatric Adrenocortical Tumors.

Authors:  Sebastiao N Martins-Filho; Madson Q Almeida; Ibere Soares; Alda Wakamatsu; Venancio Avancini F Alves; Maria Candida Barisson V Fragoso; Maria Claudia N Zerbini
Journal:  Endocr Pathol       Date:  2021-01-14       Impact factor: 3.943

Review 7.  Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature.

Authors:  Kerollos N Wanis; Rani Kanthan
Journal:  World J Surg Oncol       Date:  2015-03-24       Impact factor: 2.754

8.  Low DICER1 expression is associated with poor clinical outcome in adrenocortical carcinoma.

Authors:  Gabriela Resende Vieira de Sousa; Tamaya C Ribeiro; Andre M Faria; Beatriz M P Mariani; Antonio M Lerario; Maria Claudia N Zerbini; Iberê C Soares; Alda Wakamatsu; Venancio A F Alves; Berenice B Mendonca; Maria Candida B V Fragoso; Ana Claudia Latronico; Madson Q Almeida
Journal:  Oncotarget       Date:  2015-09-08

Review 9.  MicroRNA era: the importance for diagnosis and prognosis of adrenocortical tumors.

Authors:  João Evangelista Bezerra; Ana Claudia Latronico
Journal:  Biomed Res Int       Date:  2014-06-23       Impact factor: 3.411

10.  Metabolic reprogramming: a new relevant pathway in adult adrenocortical tumors.

Authors:  Céline Pinheiro; Sara Granja; Adhemar Longatto-Filho; André M Faria; Maria C B V Fragoso; Silvana M Lovisolo; Antonio M Lerário; Madson Q Almeida; Fátima Baltazar; Maria C N Zerbini
Journal:  Oncotarget       Date:  2015-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.